Vaxart director gets 39K shares, 78K options

Vaxart, Inc. director Watson W. Mark reported compensation-related equity awards.

Rhea-AI Filing Summary

Vaxart, Inc. director Watson W. Mark reported compensation-related equity awards. He acquired 39,400 shares of common stock at no cost in connection with restricted stock units, and a grant of 78,700 stock options with a $0.5149 exercise price, expiring July 16, 2036. Both the shares and options are scheduled to vest on the earlier of the date immediately prior to Vaxart’s 2027 annual stockholders’ meeting and July 16, 2027. Following these awards, he directly holds 173,525 common shares and 78,700 options.

Insider Trade Summary

Grant/Award: 118,100 shares

Grant/Award 2 txns

Insider Watson W. Mark

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Options (right to buy) F2	78,700	$0.00	$0.00
Grant/Award	Common Stock F1	39,400	$0.00	$0.00

Holdings After Transaction: Stock Options (right to buy) — 78,700 contracts (Direct); Common Stock — 173,525 shares (Direct)

Footnotes (2)

1. F1. Grant of shares upon vesting of restricted stock units. The shares underlying the award shall vest on the earlier of the date immediately prior of the 2027 annual meeting of stockholders of the Issuer and July 16, 2027, the first anniversary date of the grant.
2. F2. The shares subject to this option shall vest on the earlier of the date immediately prior of the 2027 annual meeting of stockholders of the Issuer and July 16, 2027, the first anniversary of the date of the grant.

Key Figures

Common shares granted: 39,400 shares Stock options granted: 78,700 options Option exercise price: $0.5149 per share +3 more

6 metrics

Common shares granted 39,400 shares Grant related to restricted stock units on 2026-07-16

Stock options granted 78,700 options Director option award on 2026-07-16

Option exercise price $0.5149 per share Conversion or exercise price for 78,700 options

Option expiration date 2036-07-16 Expiration for stock options granted on 2026-07-16

Shares after transaction 173,525 shares Total common stock directly held after equity grants

Vesting latest date July 16, 2027 Latest vesting date for both RSU-related shares and options

Key Terms

restricted stock units, Stock Options (right to buy), exercise price, annual meeting of stockholders

4 terms

restricted stock units financial

"Grant of shares upon vesting of restricted stock units."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Stock Options (right to buy) financial

"security_title": "Stock Options (right to buy)""

exercise price financial

"conversion_or_exercise_price": "0.5149""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

annual meeting of stockholders financial

"earlier of the date immediately prior of the 2027 annual meeting of stockholders"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider equity awards were reported at Vaxart (VXRT)?

Director Watson W. Mark received equity awards consisting of 39,400 common shares and 78,700 stock options. These are compensation-related grants, not open-market purchases, and were reported as acquisitions on the insider ownership report.

How many Vaxart (VXRT) shares does Watson W. Mark hold after these awards?

After the reported grants, Watson W. Mark directly holds 173,525 shares of Vaxart common stock. He also holds 78,700 stock options that are exercisable into common shares, subject to the vesting conditions described in the filing.

What are the terms of the new stock options granted at Vaxart (VXRT)?

The director was granted 78,700 stock options with an exercise price of $0.5149 per share, expiring on July 16, 2036. These options relate to an equal number of common shares and vest based on a defined future schedule.

When do the new Vaxart (VXRT) equity awards vest?

Both the 39,400-share award tied to restricted stock units and the 78,700 stock options vest on the earlier of the date immediately prior to Vaxart’s 2027 annual stockholders’ meeting and July 16, 2027, the first anniversary of the grant.

Were the Vaxart (VXRT) insider transactions under a Rule 10b5-1 plan?

The filing’s Rule 10b5-1 checkbox is marked as false, indicating these compensation grants were not reported as made under a Rule 10b5-1 trading plan. They are standard director equity awards rather than pre-planned market trades.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/17/2026 - 09:50 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Watson W. Mark

(Last) (First) (Middle)

C/O VAXART, INC.

310 UTAH AVENUE, SUITE 150

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Vaxart, Inc. [ VXRT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/16/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/16/2026		A		39,400(1)	A	$0	173,525	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options (right to buy)	$0.5149	07/16/2026		A		78,700		(2)	07/16/2036	Common Stock	78,700	$0	78,700	D

Explanation of Responses:

1. Grant of shares upon vesting of restricted stock units. The shares underlying the award shall vest on the earlier of the date immediately prior of the 2027 annual meeting of stockholders of the Issuer and July 16, 2027, the first anniversary date of the grant.

2. The shares subject to this option shall vest on the earlier of the date immediately prior of the 2027 annual meeting of stockholders of the Issuer and July 16, 2027, the first anniversary of the date of the grant.

	/s/ Edward Berg, Attorney-in-Fact	07/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)